<DOC>
	<DOCNO>NCT02805361</DOCNO>
	<brief_summary>REWARD Non Interventional study aim describe change clinical outcome Type 2 Diabetes Mellitus patient treat Dapagliflozin period one year include fasting period Ramadan .</brief_summary>
	<brief_title>Real World Assessment Clinical Outcome Changes -Including Month Ramadan-for Dapagliflozin Management Type II Diabetes Mellitus</brief_title>
	<detailed_description>REWARD multi-center , post-authorization , prospective , open label , non-interventional , real-life , observational , cohort study . The study conduct 10-15 site . Aims describe change clinical outcome 1 year follow : 1 . Primary Objective : To describe change HbAlc baseline parameter blood glucose control . 2 . Secondary Objective : To describe change baseline follow parameter : - Total body weight . - Total cholesterol , LDL-C , non-HDL-C triglyceride . - Systolic Diastolic Blood Pressures . 3 . Other Objective : To capture frequency &amp; incidence following report adverse event : - Hypoglycemic episode . - Volume Depletion . - Genital infection . - Urinary tract infection . 4 . Exploratory Objective : To describe combined effect hot climate season fast Ramadan level total ketone body level T2DM subject treat Dapagliflozin.Description outcome variable relation objective hypothesis</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>The target population select accord follow inclusion criterion : Males females participant age 18 year old diagnose type 2 Diabetic patient ( Based American Diabetes Association diagnostic criterion ( ADA ) , The ADA define diabetes fast blood glucose ( FBG ) ≥ 126mg/dL 2hour glucose level post oral glucose tolerance test ( OGTT ) ≥ 200 mg/dL HbAJC ≥ 6.5 % ) . Patients treat Dapagliflozin ( per routine care compliance locally approve prescribe information ) ≥ 4 week ≤ 16 week prior recruitment date . Patients CrCl &gt; 60 ml/min eGFR &gt; 60 ml/min/1.73 m2 include trial . Patients provide write informed consent . Patients contraindication Dapagliflozin per locally approve prescribe information exclude study . If participate clinical trial , subject take part study . Patients clinically significant renal , hepatic , haematological , oncological , endocrine , psychiatric rheumatic disease . Patients n't disease life expectancy 1 year . Patients CrCl &lt; 60 ml/min eGFR &lt; 60 ml/min/1.73 m2 exclude trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>